ClinicalTrials.gg
CompletedNCT04470154Updated Aug 9, 2022

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis

A Phase 2 interventional study of Stage I:HSK21542 0.05 μg/kg and Stage I:HSK21542 0.15 μg/kg in Uremic Pruritus, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-09.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Pruritus with a site in China — 18 open to participants now, 20 under way, 4 of them phase 3. Pruritus · China.

Enrollment
18th of 46
131 · median 92
Started
2020
with 5 others
Phase 2
7 of 48
3 open now
Registered
14th of 48
by date
Lead sponsor
3 of 48
Haisco Pharmaceutical Group Co., Ltd.

Among the 48 studies in Pruritus with a site in China, this one is the 18th largest by enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2020, is one of 7 in phase 2, and was the 14th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

18 of the 48 studies in Pruritus with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Pruritus with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled phase II clinical trial. The main objective is to evaluate the safety, pharmacokinetics, and efficacy of HSK21542 injection in subjects undergoing hemodialysis

Read the detailed description

This study is a multicenter study, which is divided into two stages. The first stage is a dose escalation, randomized, double-blind, placebo-controlled study of multiple intravenous administration within one week in hemodialysis subjects. The second stage is a randomized, double-blind, placebo-controlled study of Administration for 12 weeks in hemodialysis subjects with moderate or severe pruritus. In the second stage, consist of a Screening Visit, a 7-day Run-in Period, a 12 week Double-blind Treatment Period, and a 2-week Discontinuation Period. Informed consent will be obtained prior to performing any study-specific procedures. The Screening Visit will occur within 8 to 28 days prior to randomization to assess eligibility.

03

Conditions studied

  • Uremic Pruritus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Stage1: Inclusion Criteria:

  1. Subjects who are willing to sign an form, fully understand the objectives and purposes of the study, and are willing to comply with the study protocol before any of the study-related procedures start;
  2. Aged ≥ 18 and ≤ 75 years old, male or female;
  3. Dry weight ≥ 50.0 kg at screening, (BMI = weight (kg) / height2 [m2]) in the range of 16.0-30.0 kg/m\^2 (inclusive);
  4. Patients with end-stage renal diseases who receive hemodialysis (including hemodiafiltration) 3 times in a week prior to screening for at least 3 months;
  5. Patients with at least two occurrences of single-compartment urea clearance (sp Kt/V, see Appendix 7 for the calculation formula) ≥ 1.2, or at least two occurrences of urea reduction ratio (URR) ≥ 65%, or one occurrence of sp Kt/V ≥ 1.2 and one occurrence of URR ≥ 65% on different days of dialysis within 3 months before screening;
  6. Male subjects must agree to use condoms in sexual intercourse during the study and within 3 months after the last dose; female subjects should have had menopause for at least one year, or should have had permanent sterilization (e.g., fallopian tube occlusion, hysterectomy, bilateral salpingectomy); or women of must agree to take effective measures during the study and within 3 months after the last dose, such as oral contraceptives, condoms, and contraceptive films.

Stage1: Exclusion Criteria:

  1. Expected to undergo kidney transplantation and/or parathyroidectomy during the study;
  2. History of allergy to opioids, such as urticaria (Note: adverse effects related to opioid use, such as constipation and nausea, are not included as the exclusion criteria in this study);
  3. Used opioids within one week before screening, or unable to avoid the use of opioids other than the product during the study;
  4. Participated in any clinical trial of other drug or medical device within 1 month before screening (received study medication or treated by the medical device in the clinical trial);
  5. Used blood perfusion within 3 months before screening;
  6. History of medication or drug abuse;
  7. Average daily alcohol consumption greater than 15 g (15 g of alcohol is equivalent to 450 mL of beer or 150 mL of wine or 50 mL of light liquor) within 3 months before screening;
  8. Unable to comply with the standard dietary plan and unable to avoid coffee or tea during the study;
  9. Blood pressure of upper limbs in the supine position at screening: systolic blood pressure \< 90 mmHg, or diastolic blood pressure \< 60 mmHg, or systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg;
  10. (NYHA) Class ≥ III at screening; or confirmed to have abnormal at screening and determined by the investigator to be inappropriate to be enrolled, including ≥ 480 ms;
  11. (ALT) or aspartate aminotransferase (AST) or total ≥ 1.5 × (ULN) at screening;
  12. Blood sodium > 155 mmol/L at screening;
  13. ≤ 80 g/L at screening;
  14. Positive for surface antigen (HBsAg), antibody (HCVAb), syphilis antibody, or (HIV) antibody at screening;
  15. Underwent major surgery (determined by the investigator as major surgery) within 3 months before screening;
  16. Having a total blood loss of ≥ 200mL within 1 month before screening, except for the blood loss during menstruation in females;
  17. Females who are pregnant or breastfeeding;
  18. Any physiological or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial, as judged by the study physician, including but not limited to:

    1. Severe mental illness or cognitive impairment (e.g., dementia);
    2. Any other relevant acute or chronic neurological and psychiatric diseases (e.g., encephalopathy, coma, delirium) within 3 months before screening;
    3. Patients with malignant tumors (including malignant tumors that have been cured without recurrence).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Stage I: 0.05 μg/kg

    IV HSK21542 0.05 μg/kg solution(active or placebo) administered after each dialysis session within 2h±30 min (3 times/week).

    Drug: Stage I:HSK21542 0.05 μg/kg

  • Experimental
    Stage I: 0.15 μg/kg

    IV HSK21542 0.15 μg/kg solution(active or placebo) administered after each dialysis session within 2h±30 min (3 times/week).

    Drug: Stage I:HSK21542 0.15 μg/kg

  • Experimental
    Stage I: 0.30 μg/kg

    IV HSK21542 0.30 μg/kg solution(active or placebo) administered after each dialysis session within 2h±30 min (3 times/week).

    Drug: Stage I:HSK21542 0.30 μg/kg

  • Experimental
    Stage I: 0.80 μg/kg

    IV HSK21542 0.80 μg/kg solution(active or placebo) administered after each dialysis session within 2h±30 min (3 times/week).

    Drug: Stage I:HSK21542 0.80 μg/kg

  • Experimental
    Stage II: 0.3 μg/kg

    IV HSK21542 0.3 μg/kg solution(active or placebo) administered after each dialysis session within 10 min (3 times/week).

    Drug: Stage II:HSK21542 0.3 μg/kg

  • Experimental
    Stage II: 0.6 μg/kg

    IV HSK21542 0.3 μg/kg solution(active or placebo) administered after each dialysis session within 10 min (3 times/week).

    Drug: Stage II:HSK21542 0.6 μg/kg

Interventions

  • DrugStage I:HSK21542 0.05 μg/kg

    Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg

  • DrugStage I:HSK21542 0.15 μg/kg

    Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg

  • DrugStage I:HSK21542 0.30 μg/kg

    Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg

  • DrugStage I:HSK21542 0.80 μg/kg

    Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg

  • DrugStage II:HSK21542 0.3 μg/kg

    Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group

  • DrugStage II:HSK21542 0.6 μg/kg

    Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group

06

What researchers measure

Primary outcomes

  1. Stage I:Safety of HSK21542 injection for multiple times within one week in hemodialysis subjects

    Adverse events (AEs) and serious adverse events (SAEs),Vital signs、Physical examination, Laboratory examination, ECG

    Time frame: From screening up to D14

  2. Stage II:At week 12, the change in weekly average of daily Worst Itch NRS (WI-NRS) from baseline in subjects undergoing hemodialysis

    Change from baseline in average NRS score of itch at week 12

    Time frame: 12 week

Secondary outcomes

  1. Stage I:Area under the plasma concentration versus time curve (AUC)

    Plasma HSK21542 Area Under the Concentration-time Curve (AUC)

    Time frame: 1 week

  2. Stage I:Time to the peak plasma concentration (Tmax)

    Time to Maximum Plasma HSK21542 Concentration

    Time frame: 1 week

  3. Stage I:Maximum Concentration (Cmax)

    Maximum Concentration of HSK21542

    Time frame: 1 week

  4. Stage I:Half-time (T1/2)

    Half-time of HSK21542

    Time frame: 1 week

  5. Stage I:Total body clearance following intravenous administration (CL)

    Total body clearance following intravenous administration of HSK21542

    Time frame: 1 week

  6. Stage I:Volume of distribution following intravenous administration (Vss)

    Volume of distribution following intravenous administration of HSK21542

    Time frame: 1 week

  7. Stage I:trough concentration (Cmin)

    trough concentration of HSK21542

    Time frame: 1 week

  8. Stage I:Change from baseline in average daily Worst Itch NRS (WI-NRS) and Itch-related Quality of Life as Assessed by Skindex-16 Scale Score

    Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". The Skindex-16 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. The Skindex-16 has 16 questions; the total Skindex-16 score ranges from 0 to 100. A higher total score represents worse quality of life.

    Time frame: 1 week

  9. Stage I:Correlation between prolactin level and drug exposure of HSK21542 injection in hemodialysis subjects

    Detect prolactin concentration before and after administration

    Time frame: 1 week

  10. Stage II: Safety of HSK21542 injection in the treatment of moderate and severe pruritus in hemodialysis subjects for 12 weeks

    Adverse events (AEs) and serious adverse events (SAEs),Vital signs、Physical examination, Laboratory examination, ECG

    Time frame: 12 weeks

  11. Stage II:Area under the plasma concentration versus time curve (AUC)

    Plasma Area Under the Concentration-time Curve of HSK21542

    Time frame: 12 weeks

  12. Stage II:Time to Maximum plasma concentration (Tmax)

    Time to Maximum Plasma Concentration of HSK21542

    Time frame: 12 weeks

  13. Stage II:Maximum Concentration (Cmax)

    Maximum Concentration of HSK21542

    Time frame: 12 weeks

  14. Stage II:Half-time (T1/2)

    Half-time (T1/2) of HSK21542

    Time frame: 12 weeks

  15. Stage II:Total body clearance following intravenous administration (CL)

    Total body clearance following intravenous administration of HSK21542

    Time frame: 12 weeks

  16. Stage II:Volume of distribution following intravenous administration (Vss)

    Volume of distribution following intravenous administration of HSK21542

    Time frame: 12 weeks

  17. Stage II: The proportion of subjects change from baseline ≥3 points with respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS Score at Week 12

    Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used logistic and Log-binomial regression model.

    Time frame: 12 week

  18. Stage II: The proportion of subjects change from baseline ≥4 points with respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS Score at Week 12

    Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used logistic and Log-binomial regression model.

    Time frame: 12 week

  19. Stage II:Change from baseline in Itch-related Quality of Life as Assessed by Skindex-16 and 5-D Scale Score

    The Skindex-16 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. The Skindex-16 has 16 questions; the total Skindex-16 score ranges from 0 to 100. A higher total score represents worse quality of life. The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the duration of itch/day, degree, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. The 5-D Itch Scale has 5 questions; the total 5-D Itch Scale score ranges from 5 to 25, with higher scores indicating worse responses.

    Time frame: 12 week

  20. Stage II: Weekly mean value of the daily 24-hour Worst Itching Intensity NRS Score within 2 weeks after drug withdrawal after 12 weeks of administration

    Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable".

    Time frame: 14 week

  21. Stage II: Weekly mean value of the ShOWS and OOWS Score within 2 weeks after drug withdrawal after 12 weeks of administration

    According to the weekly mean of ShOWS and OOWS scores, combined with AE, comprehensively evaluate whether there is drug withdrawal reaction.

    Time frame: 14 week

  22. Stage II: Change from baseline in the level of serum IL-6,IL-31,TNF-α,and hs-CRP

    Evaluate the effect of HSK21542 on IL-6, IL-31, TNF- α and hs-CRP levels.

    Time frame: 12 weeks

  23. Stage II: Change from baseline in the level of serum iPTH

    Evaluate the effect of HSK21542 on iPTH levels.

    Time frame: 12 weeks

07

Study locations

1 site
  • Guizhou Medical University Affiliated Hospital
    Guiyang, Guizhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2021, 14 months.

Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 14 months is close to that.

Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 14, 2020
StartActual
Aug 10, 2020
Primary completionActual
Oct 28, 2021
CompletionActual
Oct 28, 2021
Last update
Aug 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04470154
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Aug 10, 2020
Primary completion
Oct 28, 2021
Completion
Oct 28, 2021
Last update
Aug 9, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion